Regenerx Biopharm In Insiders
RGRXDelisted Stock | USD 0.03 0.01 25.00% |
Regenerx Biopharm employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 64 years, averaging almost 21.0 years of service per executive, having 1.0 employees per reported executive. Break down of Regenerx Biopharm's management performance can provide insight into the company performance.
J Finkelstein CEO CEO and President and Director |
Allan Goldstein Chairman Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board |
Regenerx |
Regenerx Biopharm Management Team Effectiveness
The company has return on total asset (ROA) of (0.8397) % which means that it has lost $0.8397 on every $100 spent on assets. This is way below average. Regenerx Biopharm's management efficiency ratios could be used to measure how well Regenerx Biopharm manages its routine affairs as well as how well it operates its assets and liabilities.Regenerx Biopharm Workforce Comparison
Regenerx Biopharm In is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 374. Regenerx Biopharm maintains roughly 3.0 in number of employees contributing less than 1% to equities under Health Care industry.
Regenerx Biopharm Notable Stakeholders
A Regenerx Biopharm stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Regenerx Biopharm often face trade-offs trying to please all of them. Regenerx Biopharm's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Regenerx Biopharm's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
J Finkelstein | CEO and President and Director | Profile | |
Allan Goldstein | Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board | Profile | |
Nabila Turjman | Ex Affairs | Profile |
About Regenerx Biopharm Management Performance
The success or failure of an entity such as Regenerx Biopharm often depends on how effective the management is. Regenerx Biopharm management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Regenerx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Regenerx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. REGENERX BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
The data published in Regenerx Biopharm's official financial statements typically reflect Regenerx Biopharm's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Regenerx Biopharm's quantitative information. For example, before you start analyzing numbers published by Regenerx accountants, it's essential to understand Regenerx Biopharm's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Regenerx Biopharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Regenerx Biopharm In. Check Regenerx Biopharm's Beneish M Score to see the likelihood of Regenerx Biopharm's management manipulating its earnings.
Regenerx Biopharm Workforce Analysis
Traditionally, organizations such as Regenerx Biopharm use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Regenerx Biopharm within its industry.Regenerx Biopharm Manpower Efficiency
Return on Regenerx Biopharm Manpower
Revenue Per Employee | 25.6K | |
Revenue Per Executive | 25.6K | |
Net Loss Per Employee | 532.6K | |
Net Loss Per Executive | 532.6K | |
Working Capital Per Employee | 268.7K | |
Working Capital Per Executive | 268.7K |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |